newsfilter
← Latest News
Business Wire·

Sail Biomedicines Provides Update on Research with Cystic Fibrosis Foundation and Pioneering Medicines

- Research aims to leverage Sail's Endless RNA™ (eRNA™) platform as a novel therapeutic approach to treating the 10%-15% of people with cystic fibrosis (CF) who are genetically defined as ineligible for,